Medical Device

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that it has closed its acquisition of 23.8% of the issued and outstanding shares of each of Shaw Vision Inc. ("Shaw Vision") and Shaw Lens Inc. ("Shaw Lens") from a minority shareholder (the "Shaw Acquisition"), as originally announced on August 31, 2021.

The Shaw Acquisition has been approved by the boards of Shaw Vision and Shaw Lens. Closing of the Shaw Acquisition and has received final consent of the TSX Venture Exchange.

All securities issued will be subject to a hold period of four months and one day pursuant to applicable securities laws.

Both Shaw Vision Inc. and Shaw Lens Inc. are Toronto-based privately owned federal corporations.

About Shaw Lens and Shaw Vision

Shaw Lens holds a U.S. patent protected lens technology that can solve a condition for people who wear glasses, known as aniseikonia. It is a condition that causes each eye to perceive the size of objects differently. Issues related can include headaches, double vision, disorientation or dizziness, tearing, eye pain or fatigue, sensitivity to light, visual acuity issues and trouble reading, as well as nausea…according to the Columbia University Department of Ophthalmology… "20-30% of the general spectacle wearing population may have a measurable amount of aniseikonia." The potential market size for corrective lenses for aniseikonia is over 800 million people that may be currently living with some degree of aniseikonia and its relative effects.

More information about Shaw can be found at

About Leveljump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) is building a national medical diagnostic imaging company and brand, primarily by providing teleradiology (remote radiology) services to its client hospitals and imaging centers. Additionally, JUMP plans to expand through the acquisition of independent healthcare facilities focused on diagnostic imaging as well as acquiring new disruptive imaging technologies.

LevelJump Healthcare Corp.

Mitchell Geisler, Chief Executive Officer
(833) 840-2020


This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

To view the source version of this press release, please visit

News Provided by Newsfile via QuoteMedia

Graphene Manufacturing Group Announces Closing of $5.7M Bought Deal Offering

Graphene Manufacturing Group Announces Closing of $5.7M Bought Deal Offering

Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to announce that the Company closed its previously announced bought deal prospectus offering of units (the "Units") of the Company, including exercise in full of the over-allotment option (the "Offering"). A total of 2,091,850 Units were sold at a price of C$2.75 per Unit (the "Offering Price") for gross proceeds of approximately C$5.75 million.

Each Unit is comprised of one ordinary share in the capital of the Company (each, an "Ordinary Share") and one Ordinary Share purchase warrant (each, a "Warrant"). Each Warrant entitles the holder to purchase one Ordinary Share at a price of C$3.35, at any time until November 30, 2026. The Offering was completed pursuant to an underwriting agreement dated November 14, 2022 among the Company and Eight Capital, as lead underwriter and sole bookrunner, and a syndicate of underwriters including Raymond James Ltd., H.C. Wainwright & Co., LLC, Leede Jones Gable Inc., PI Financial Corp., and Research Capital Corporation (collectively, the "Underwriters").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the "Agreement") with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer.

This press release features multimedia. View the full release here:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Greenlane Renewables Announces Dairy RNG System Sales Contract

Greenlane Renewables Announces Dairy RNG System Sales Contract

~Greenlane to supply a biogas upgrading system for a new project in the Western U.S.~

 Greenlane Renewables Inc. (" Greenlane ") (TSX: GRN) (FSE: 52G) is pleased to announce that its wholly-owned subsidiary, Greenlane Biogas North America Ltd., has been awarded a $4.6 million ( US$3.5 million ) contract for a dairy RNG project in the Western United States for the supply of a biogas upgrading system. Greenlane will supply its pressure swing adsorption system for upgrading biogas generated from anaerobic digestion of dairy cow manure into carbon negative renewable natural gas ("RNG") suitable for injection into the local pipeline network. Order fulfillment is expected to commence immediately.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin states, "As we continue to focus our efforts and resources on PlanteinTM Plant-Based Foods and our ten (10) year exclusive manufacturing and distribution agreement with Flexitarian Foods PTY Ltd., there have been many positives as well as a number of challenges. The positives include our recent launch into retail, and the return to trade shows where are products have been getting exceptional reviews, as well as our expanding relations with our national distributors. However, the Company has experienced significant challenges as well, the most notable being the continued delay of customized manufacturing lines being assembled in Shanghai, China. The delay to date has been due to a combination of shortage of computer chips, combined with on-going Covid challenges and subsequent quarantining in Shanghai".

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Nanalysis Reports Third Quarter 2022 Results

Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR machines and MRI technology for healthcare and industrial applications, releases its second quarter results ending September 30, 2022. Chief Executive Officer, Sean Krakiwsky and Interim Chief Financial Officer, Randall McRae will host a conference call at 5 P.M. Eastern Time today to discuss the results. A second call will be held for European investors at 8:30am ET on Wednesday, November 30 th . All interested parties are invited to join these calls.

Nanalysis Scientific Corp. (CNW Group/Nanalysis Scientific Corp.)

"I am pleased to report we have returned to our strong growth trajectory in the third quarter," said Sean Krakiwsky, Founder and CEO of Nanalysis. "We continue to focus on growing all segments of our organization and executing on our operational strategy. In the third quarter we laid significant groundwork on our previously announced multi-year airport security contract with the Canadian Air Transportation Security Authority and have now begun operations on that project in the fourth quarter. We believe we have also resolved the issues that slowed our growth in our benchtop NMR sales organization in the second quarter, returning to strong benchtop NMR sales figures. We expect to see continued strength in our business in the fourth quarter, which has historically been a strong quarter for our business."

Financial highlights (unaudited) for the three months ended September 30, 2022:

  • For the three months ended September 30, 2022 , the Company reported consolidated revenue of $6,878K , an increase of $3,542K or 106% from the comparative period in 2021. This includes $6,145K in product sales and $733K of service revenue related to airport security services.
  • Gross margin on total sales was 43% for the three months ended September 30, 2022 . This was the result of increased training costs of personnel for the CATSA airport security project, increased personnel and training in Nanalysis' manufacturing group to increase manufacturing capacity, an increase in costs due to worldwide supply chain constraints and inflation, as well as a specific medical imaging project in our RS2D subsidiary that had lower than normal gross margins. Management expects margins to improve as continued investments in manufacturing improvements continue, sales levels increase, and the CATSA airport security project continues to phase-in to full capacity.
  • (Loss) Income before other items for the three months ended September 30, 2022, was $( 618K ) versus $12K compared to the same period last year.
  • Net loss for the three months ended was $(2,599K), as compared to the three-month loss for September 30, 2021, of $(857K).
  • The Company had cash on hand of $7,925K, an undrawn credit facility of $6,734K, working capital of $9,658K and an undrawn government contribution funding of $4,985K as of September 30, 2022.

Recent strategic and operational highlights during and subsequent to the second quarter of 2022 include:

  • Funding received from Prairies Economic Development Canada: Subsequent to September 30, 2022 , the Company received its first $1.5 million in funding from the Business Scale-up Program. This program will provide Nanalysis up to $4,985K of funding in the form of an unsecured interest free loan. The program is designed to help fast growing tech firms scale-up and enter new markets.
  • Consolidation of credit facility: On November 18, 2022 , the Company closed a credit line with a major Canadian bank, consolidating its existing operating facilities into a $9 million operating line.  The line bears interest at a rate of prime plus 0.65% and will allow the Company to execute on its growth and expansion plans.
  • Security Service : In November 2022 , the Company began providing services under the CATSA airport security contract and continues to execute successfully on its phase-in plan for the entire project.
  • Manufacturing : In addition to Nanalysis investing in a state of the art five axis machining centre and wire electrical discharge machine in the second quarter of 2022, Nanalysis has also invested in growing out the manufacturing team allowing the Company to meet expected growth in demand as it heads into 2023.
  • Quad Systems : The company has seen continued development with Quad System's full high-field NMR product. Module sales have continued to increase in the third quarter and the Company expects material revenue from the acquisition in 2023.
Operating Results

For the nine months ended September 30, 2022 , the Company reported consolidated revenue of $17,618K , an increase of $6,664K or 61% from the comparative period in 2021. The increase from Q3 2021 can be attributed to continued increases in shipments of the 100MHz benchtop NMR unit, coupled with revenue from the recent acquisition, K'Prime, offset by lower RS2D revenue than in Q3 2021.

Gross profit for the nine months ended September 30, 2022 , was $9,504K (a margin of 54%) compared to gross profit of $7,152K (a margin of 65%) for the nine months ended September 30, 2021 . Margins for the nine months ended September 30, 2022 , decreased over the nine months ended September 30, 2021 , as a result of increased component costs because of world-wide supply chain challenges, low margins on a specific Q3 project in RS2D, training costs included in cost of services related to the CATSA airport security project phase in, and investments made in the Company's manufacturing workforce beginning in the second quarter.

The Company's net loss for the nine months ended was $(6,623K) , as compared to the nine-month loss for the period ended September 30, 2021 , of $(1,127K) . The increased loss was due to higher sales and marketing expenses, increased general and administration expenses and increased research and development expenses, both in the Nanalysis segment and from the new acquisitions. In addition, there were business acquisition costs from the two transactions completed, increased depreciation and amortization expense, and increased finance expenses partially offset by no RS2D earnout in the quarter and increased revenues.


"Our main objective continues to be focusing on executing our business plan, including ramping up sales of our 100 MHz product, completing the roll out of the CATSA airport service contract, and capitalizing on business opportunities brought by our recent acquisitions. We have successfully restructured and refocused our benchtop NMR salesforce and expect growing demand in 2023 for benchtop products, and we continue to work towards the launch of a full multi-module high-field NMR product via Quad Systems," said Sean Krakiwsky .

"With a slower second quarter well behind us, we have returned to our high growth trajectory and continue to have confidence that Nanalysis is well positioned for solid growth in 2023 and the years to come. Operational excellence remains our mantra, as we will continue to leverage existing customer relationships, our innovative technologies, and a motivated and professional team to fuel growth. We are confident that we will deliver the value we've created by our recent acquisitions to our shareholders through the remainder of 2022 and into the new year," concluded Mr. Krakiwsky.

Conference Call

Investors interested in participating on the live call can dial 1-888-664-6392 or 416-764-8659 from abroad. Investors can also access the call online through a listen-only webcast here: or on the investor relations section of the Company's website HERE . The webcast will be archived on the Company's investor relations webpage for at least 90 days and a telephonic playback will be available for seven days after the conference call by calling 1-888-390-0541 or 416-764-8677, conference ID # 833132.

Additionally, the Company will be hosting a Q&A session for it's European investors tomorrow, Wednesday, November 30 th at 8:30am ET which can be accessed by the following link: : Click here to join the meeting , or call in (audio only) +1 437-703-4522, Phone Conference ID: 295 204 525#.

About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', OTC and the Frankfurt exchange under the ticker symbol '1N1'. The company's business is what we term "MRI and NMR for industry". The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The Company has followed up that initial offering with new products and continues to have a strong innovation pipeline. Nanalysis began selling a 100MHz device in 2020. The Company's new device is the most powerful and most advanced compact NMR device ever brought to market.  Nanalysis devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners.

With the recent acquisition of K'Prime, the Company maintains a North American sales and service company of over 40 individuals who cover scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems and services for security applications.  Additionally, the Company has a 43% ownership in Quad Systems AG ("Quad Systems"), with an option to purchase the remaining shares.  Quad Systems is a Zurich-based Nuclear Magnetic Resonance ("NMR") company focused on high-field NMR for pharmaceutical and other vertical markets.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia:

SOURCE Nanalysis Scientific Corp.

Cision View original content to download multimedia:

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Avricore Health Reports Third-Quarter 2022 Results

Avricore Health Reports Third-Quarter 2022 Results

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") today released its Q3 results which demonstrate significant revenue growth, indicating it can scale sustainably and deliver on its long-term objectives.

The Company's objective to create the world's first cloud-connected point-of-care network in community pharmacy is on track to becoming a reality, bringing powerful health screening and data management tools to community pharmacies and ensuring better outcomes for patients.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News